0000899243-22-035922.txt : 20221115 0000899243-22-035922.hdr.sgml : 20221115 20221115183857 ACCESSION NUMBER: 0000899243-22-035922 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221110 FILED AS OF DATE: 20221115 DATE AS OF CHANGE: 20221115 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sorrento Therapeutics, Inc. CENTRAL INDEX KEY: 0000850261 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39852 FILM NUMBER: 221392538 BUSINESS ADDRESS: STREET 1: 4955 DIRECTORS PLACE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-203-4100 MAIL ADDRESS: STREET 1: 4955 DIRECTORS PLACE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER NAME: FORMER CONFORMED NAME: QUIKBYTE SOFTWARE INC DATE OF NAME CHANGE: 19920703 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vickers Vantage Corp. I CENTRAL INDEX KEY: 0001820190 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 960 SAN ANTONIO ROAD CITY: PALO ALTO STATE: CA ZIP: 94303 BUSINESS PHONE: (650) 516-4310 MAIL ADDRESS: STREET 1: 960 SAN ANTONIO ROAD CITY: PALO ALTO STATE: CA ZIP: 94303 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-11-10 0 0001820190 Vickers Vantage Corp. I SCLX 0000850261 Sorrento Therapeutics, Inc. 4955 DIRECTORS PLACE SAN DIEGO CA 92121 0 0 1 0 Warrant to Purchase Common Stock 11.50 2022-11-10 4 J 0 2796704 A 2022-11-10 2027-11-10 Common Stock 2796704 2796704 D Warrant to Purchase Common Stock 11.50 2022-11-10 4 J 0 307296 A 2022-11-10 2027-11-10 Common Stock 307296 3104000 D Reflects the assignment and transfer of the warrant to the Reporting Person by Vickers Venture Fund VI Pte Ltd ("Sponsor One") pursuant the Warrant Transfer Agreement (as described below). Reflects the assignment and transfer of the warrant to the Reporting Person by Vickers Venture Fund VI (Plan) Ltd ("Sponsor Two" and together with Sponsor One, the "Sponsors") pursuant the Warrant Transfer Agreement (as described below). Pursuant to the warrant transfer agreement, dated as of October 12, 2022 (the "Warrant Transfer Agreement"), by and among the Reporting Person, the Sponsors, Vickers Vantage Corp. I ("Vickers") and Maxim Group LLC, Sponsor One transferred 2,796,704 warrant an aggregate of 3,104,000 warrants to the Reporting Person as over 90% of the public Vickers ordinary shares outstanding as of March 17, 2022 were redeemed in connection with the business combination as further described in Vickers' final prospectus and definitive proxy statement, dated October 28, 2022 (the "Proxy Statement/Prospectus") and filed with the Securities and Exchange Commission. The Warrant Transfer Agreement was entered into as consideration for the Reporting Person entering into a letter agreement with Scilex Holding Company ("Scilex") pursuant to which the Reporting Party would fund a loan to Scilex upon its request in the maximum aggregate amount of $10,000,000, as further described in the Proxy Statement/Prospectus. /s/ Jaisim Shah, as Attorney-in-Fact 2022-11-15